Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$33.35 USD
-1.86 (-5.28%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $33.38 +0.03 (0.09%) 7:12 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 375 | 407 | 442 | 296 | 92 |
Receivables | 15 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 12 | 9 | 6 | 1 |
Total Current Assets | 405 | 419 | 451 | 302 | 93 |
Net Property & Equipment | 48 | 13 | 12 | 11 | 4 |
Investments & Advances | 61 | 152 | 125 | 163 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 9 | 8 | 2 | 2 |
Total Assets | 576 | 603 | 606 | 487 | 117 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 4 | 4 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 34 | 28 | 23 | 10 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 38 | 36 | 62 | 93 | 23 |
Total Current Liabilities | 86 | 71 | 93 | 111 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 17 | 28 | 39 | 78 | 30 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 181 | 113 | 146 | 203 | 82 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 109 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 926 | 879 | 689 | 413 | 2 |
Retained Earnings | -531 | -384 | -229 | -129 | -76 |
Other Equity | -1 | -5 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 395 | 490 | 460 | 284 | 35 |
Total Liabilities & Shareholder's Equity | 576 | 603 | 606 | 487 | 117 |
Total Common Equity | 395 | 490 | 460 | 284 | -74 |
Shares Outstanding | 55.40 | 54.80 | 51.30 | 44.40 | NA |
Book Value Per Share | 7.13 | 8.94 | 8.96 | 6.39 | 0.00 |
Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 375 | 358 | 368 | 397 |
Receivables | NA | 15 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 15 | 18 | 18 | 15 |
Total Current Assets | NA | 405 | 376 | 385 | 412 |
Net Property & Equipment | NA | 48 | 36 | 27 | 17 |
Investments & Advances | NA | 61 | 77 | 105 | 119 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 8 | 9 | 9 | 9 |
Total Assets | NA | 576 | 552 | 582 | 614 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 5 | 4 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 1 | 1 | 1 |
Accrued Expenses | NA | 34 | 26 | 22 | 19 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 38 | 28 | 25 | 33 |
Total Current Liabilities | NA | 86 | 63 | 55 | 62 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 17 | 16 | 20 | 25 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 181 | 157 | 147 | 152 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 926 | 914 | 903 | 890 |
Retained Earnings | NA | -531 | -516 | -464 | -425 |
Other Equity | NA | -1 | -2 | -4 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 395 | 396 | 435 | 462 |
Total Liabilities & Shareholder's Equity | NA | 576 | 552 | 582 | 614 |
Total Common Equity | 0 | 395 | 396 | 435 | 462 |
Shares Outstanding | 61.10 | 55.40 | 55.40 | 55.40 | 55.30 |
Book Value Per Share | 0.00 | 7.13 | 7.14 | 7.86 | 8.35 |